Shares of Axsome Therapeutics surged 6% to $234.24 after the brain-health drugmaker reported Q2 results that showed accelerating demand across its product lineup and a key regulatory win — even as losses widened and revenue narrowly missed Wall Street's target.
The company posted $218.4 million in net product revenue, up 46% year over year but just shy of the $221.9 million analysts expected.
Its per-share loss of $0.99 was also wider than the $0.85 consensus. Investors shrugged off both misses, focusing instead on what's selling and what's coming next.
The Depression Drug Is Carrying the Business — and Getting a Second Life
AUVELITY, Axsome's flagship depression treatment, remains the revenue engine. Roughly 266,000 total prescriptions were written for AUVELITY in Q2, up 34% year over year. But the bigger story is the Alzheimer's agitation expansion. The FDA approved AUVELITY on April 30 as the first non-antipsychotic drug for agitation linked to Alzheimer's disease , and Axsome launched it commercially in June. In the first eight weeks, new prescriptions among patients 65 and older jumped 126% compared to the prior period — a sign that doctors are reaching for it quickly in a patient population with very few options.
A Narcolepsy Drug Is Now Under FDA Review, With No Advisory Panel Planned
The FDA accepted for review Axsome's application for AXS-12, an investigational treatment for cataplexy — sudden muscle weakness episodes — in narcolepsy.
The agency set a decision deadline of May 1, 2027 and indicated it does not plan to convene an outside advisory panel , which typically signals a cleaner regulatory path. AXS-12 carries Orphan Drug Designation , meaning it would enjoy pricing power and market exclusivity if approved.
The Pipeline Is Deep, But the Cash Cushion Is Not Growing
CEO Herriot Tabuteau said the late-stage pipeline could support roughly one new drug application per year through 2030.
Upcoming catalysts include Phase III results in binge eating disorder in Q4 and newly started pediatric ADHD trials. However, the company posted a $51.3 million net loss and ended Q2 with approximately $320 million in cash — essentially flat since year-end. Management expects selling costs to hold near $208 million per quarter while R&D spending rises in the second half as new trials begin.
The Key Question for Shareholders
Revenue is growing fast, the Alzheimer's launch is gaining traction, and the pipeline is advancing. But at current burn rates, Axsome has roughly six quarters of runway. Whether the stock can sustain this rally hinges on whether AUVELITY's Alzheimer's expansion can drive the company toward profitability before it needs to raise more money.